Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Open access
Cobo‐Calvo, Alvaro, Ruiz, Anne, Rollot, Fabien, Arrambide, Georgina, Deschamps, Romain, Maillart, Elisabeth, Papeix, Caroline, Audoin, Bertrand, Lépine, Anne Fabienne, Maurey, Hélène, Zephir, Helene, Biotti, Damien, Ciron, Jonathan, Durand‐Dubief, Francoise, Collongues, Nicolas, Ayrignac, Xavier, Labauge, Pierre, Meyer, Pierre, Thouvenot, Eric, Bourre, Bertrand, Montcuquet, Alexis, Cohen, Mikael, Horello, Philippe, Tintoré, Mar, De Seze, Jerome, Vukusic, Sandra, Deiva, Kumaran, Marignier, Romain, the NOMADMUS, KidBioSEP, and OFSEP study groups · 2021 · Annals of Neurology

Abstract

Objective: The main objective was to compare clinical features, disease course, and myelin oligodendrocyte glycoprotein (MOG) antibody (Ab) dynamics between children and adults with MOG‐Ab–associated disease (MOGAD). Methods: This retrospective multicentric, national study included 98 children and 268 adults with MOGAD between January 2014 and September 2019. Cox regression model for recurrent time‐to‐event data and Kaplan–Meier curves for time to antibody negativity were performed for the objectives. Results: Isolated optic neuritis was the most frequent clinical presentation in both children (40.8%) and adults (55.9%, p = 0.013), and acute disseminated encephalomyelitis syndrome was more frequent in children (36.7% vs 5.6%, p < 0.001). Compared to adults, children displayed better recovery (Expanded Disability Status Scale ≥ 3.0 at last follow‐up reached only by 10 of 97 [10.3%] vs 66/247 [26.7%], p < 0.001). In the multivariate analysis, adults were at higher risk of relapse than children (hazard ratio = 1.41, 95% confidence interval [CI] = 1.12–1.78, p = 0.003). At 2 years, 64.2% (95% CI = 40.9–86.5) of nonrelapsing children became MOG‐Ab negative compared to 14.1% (95% CI = 4.7–38.3) of relapsing children (log‐rank p < 0.001), with no differences observed in adults (log‐rank p = 0.280). Interpretation: MOGAD patients differ in the clinical presentation at onset, showing an age‐related shift in the clinical features across age groups. Compared to children, adults have a higher risk of relapse and worse functional recovery. Finally, children with monophasic disease become MOG‐Ab negative earlier than relapsing children, but this is not true in adults. Considering these differences, management and treatment guidelines should be considered independently in children and adults. ANN NEUROL 2021;89:30–41

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.25909

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 270

Metadata

Authors
Cobo‐Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A. F., Maurey, H., Zephir, H., Biotti, D., Ciron, J., Durand‐Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Meyer, P., Thouvenot, E., Bourre, B., Montcuquet, A., Cohen, M., Horello, P., Tintoré, M., De Seze, J., Vukusic, S., Deiva, K., Marignier, R., & the NOMADMUS, K.
Venue
Annals of Neurology
Publisher
Wiley
Published
2020-10-15
Volume
89
Issue
1
Pages
30-41
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W3087282011
Cited by
270
References
25
FWCI
15.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. https://app.cochat.ai/papers/10.1002/ana.25909
The paper
Cobo‐Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A. F., Maurey, H., Zephir, H., Biotti, D., Ciron, J., Durand‐Dubief, F., Collongues, N., Ayrignac, X., Labauge, P., Meyer, P., Thouvenot, E., . . . the NOMADMUS, K. (2021). Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Annals of Neurology. https://doi.org/10.1002/ana.25909

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.